CN112057621B - Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection - Google Patents
Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection Download PDFInfo
- Publication number
- CN112057621B CN112057621B CN201910500724.5A CN201910500724A CN112057621B CN 112057621 B CN112057621 B CN 112057621B CN 201910500724 A CN201910500724 A CN 201910500724A CN 112057621 B CN112057621 B CN 112057621B
- Authority
- CN
- China
- Prior art keywords
- sirna
- caco
- cells
- 7member
- carrier family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of biomedicine, in particular to a new target for resisting enterovirus 71infection and application thereof. The invention takes human colon cancer cells (Caco-2) as target cells, and adopts RNA interference technology to down-regulate the expression of target cell transfer-related membrane protein to search for host factors which can effectively inhibit EV71 from infecting human colon cancer cells, thereby achieving the purpose of blocking EV71 from the source (intestinal tract). Experiments show that the solute carrier family 7member 7(SLC7A7) plays an important role in EV71 infected Caco-2 cells, the expression of SLC7A7 is reduced, and the EV71 infection can be obviously inhibited. The invention provides an application of SLC7A7in preparation of a medicine for preventing or treating enterovirus 71infection, and provides a new target and a treatment scheme for clinically preventing and treating diseases such as hand-foot-and-mouth disease, meningitis, brainstem encephalitis or poliomyelitis caused by EV71 infection.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a new target for resisting enterovirus 71infection and application thereof.
Background
Enterovirus 71 (Enterovirus 71, EV71) belongs to human enterovirus A of Enterovirus of picornaviridae, and is one of the main pathogens causing Hand-foot-and-mouth disease (HFMD). Currently, hand-foot-and-mouth disease is fulminant and prevalent in many areas of the world, especially in the asia-pacific region. In China, since the epidemic situation of the hand-foot-and-mouth disease occurs in a plurality of provinces and cities in 2008, the number of infected people and the death rate of the disease are always high, more than 100 ten thousand cases of the disease are reported every year, and the number of the death cases is nearly 1000. The main disease population of the hand-foot-and-mouth disease is infants under 5 years old, and the clinical manifestations are fever, herpes and other symptoms of hands, feet, buttocks, oral mucosa and other parts; a small number of children may develop into critically ill patients, presenting with Central Nervous System (CNS) lesions, including aseptic meningitis, brainstem encephalitis, encephalomyelitis, and neurogenic pulmonary edema, etc., that are seriously threatening the life and health of the infant (Solomon T, et al. virology, epidemiology, pathobiology, and control of infectious 71.Lancet infection dis.2010,10(11): 778-90). Hand-foot-and-mouth disease, especially severe cases, is mostly caused by enterovirus 71 (EV71) infection. However, at present, no specific and efficient antiviral drug exists for treating hand-foot-and-mouth disease caused by EV71, symptomatic treatment is mainly used clinically, and no effective vaccine appears in the aspect of prevention.
The transmission of EV71 is most widespread in the faecal-oral route, where the intestinal tract is the first barrier of the human body against pathogens. Animal experimental studies have demonstrated that EV71 is pathogen positive initially in small intestinal tissue after oral inoculation of mice [ Chen YC, et al. A Murine oral enterovirus 71infection model with central nervous system in vivo. journal of General Virology,2004,85(1):69-77 ]. Thus, EV71 first replicates rapidly in large numbers in small intestinal cells by infecting the intestinal system, and then enters the blood causing viremia and causing infection of other organs. However, the mechanism of how the virus invades the intestinal cells after EV71 reaches the human intestinal system is not clear. The small intestine is used as an important organ of a human digestive system and is mainly responsible for digestion and absorption of nutrients, and the outermost layer of the cavity surface of the small intestine is small intestine mucosal epithelial cells which play an important role in resisting pathogens. As a human colon cancer cell line, Caco-2 is similar to human small intestine mucosal epithelial cells in morphological and physiological functions, and the cultured mature Caco-2 is a compact monolayer cell with the same polarity and close connection and microvilli structure as normal small intestine mucosal epithelial cells; and as tumor cells, are easier to culture than small intestine mucosal epithelial cells. Therefore, the mechanism of the EV71 infection Caco-2 is proved, and a new antiviral target is searched based on the mechanism, so that the mechanism is important for preventing and treating EV71 infection. However, the specific molecular mechanism of EV71 infection with Caco-2 is still unclear.
When a virus infects a host, it must utilize various molecules of the host cell and related signaling pathways to complete its life cycle. Wherein, the transportation related molecules on the cell membrane have important significance for the invasion, replication and release of infectious progeny virus particles. For example, the A Disintegrin and metalloprotease domain protein 10(A Disintegrin and metalloprotease domain-binding protein, ADAM10) plays an important role in the nuclear transport and replication of HIV [ Endsley MA, et al.Nuclear affinity of the HIV-1pre-integration complex on the ADAM10 intracellular domain, virology.2014,454-455: 60-6; friedrich BM, et al. A functional role for ADAM10in human immunodeficiency virus type-1 reproduction. retrovirology.2011,8:32]. In recent years, it has also been found that ADP ribosylation factor 6(ARF6) molecule plays an important role in the infection process of Coxsackie virus A9
O,et al.Internalization of coxsackievirus A9is mediated by beta 2-microglobulin,dynamin,and ARF6but not by caveolin-1or clathrin.J Virol.2010,84(7):3666-81]. It has also been shown that EV71 infects Jurkat T lymphocytes mainly by using caveolar-dependent endocytosis pathway (CAV1) on cell membrane [ Lin HY, et al, caveolar-dependent endocytosis is requirered for human PSGL-1-mediated enterovirus 71infection. J Virol.2013,87(16):9064-76]. Furthermore, it has been found that villin 2(VIL2 or Ezrin) is involved in parvovirus replication and spread [ N ü esch JP, et al, Ezrin-radiaxin-fashion proteins in infected in partial replication and replication, J Virol, 2009,83(11):5854-63]. Therefore, the molecule related to the transport on the cell membrane becomes an important target for screening antiviral drugs.
The ATP binding cassette transmembrane transport subfamily C member 3(ABCC3) belongs to ABC transport family members, and can transport a combination of glucuronide, glutathione, sulfate and the like, as well as monoanionic bile acid. Human ABCC3 is expressed in the liver, gut, pancreas, gall bladder and kidney, and is also present in several cancers in humans, such as hepatocellular carcinoma, lung adenocarcinoma, ovarian cancer, pancreatic cancer and leukemia cells. Human ABCC3 has been reported to be involved in resistance to various antineoplastic agents by transporting drugs such as etoposide, teniposide and vincristine [ Kobayashi K, et al. functional analysis of non-synymous single nucleotide polymorphism type ATP-binding cassette transporter subunit C3. Pharmacogene et Genomics.2008,18(9):823-33 ]. Overexpression of ABCC3promotes cell proliferation, drug resistance and aerobic glycolysis and is associated with tumor progression and prognosis [ Liu X, et al. overexpression of ABCC3 proteins cell proliferation, drug resistance, and aerobic diabetes and is associated with a pore growth in cancer receptor cancer patient. Tumour biol.2016, (6) 8367-74; Carrasco-Torres G, et al, the Transmembrane transporter ABCC3 particulate matters in liquid growth and is a potential biomarker, Tumour biol.2016,37(2):2007-14 ]. Knockout of ABCC3 severely impairs liver growth induced by bile acids and delays liver regeneration after liver resection in mice [ Fern ndez-Barrena MG, et al rock of ABCC3expression impairs double-acid induced liver growth and delay liver regeneration after liver resection, j liver.2012, 56(2):367-73 ].
Solute carrier family 7member 7(SLC7a7) encodes the Y + L amino acid transporter 1, a sodium-independent amino acid transporter. The transporter is present on epithelial Cell membranes and regulates a variety of physiological functions primarily by regulating the transmembrane transport of cations and large neutral amino acids [ Ji X, et al.function of SLC7A7in T-Cell Acute lysogenic Leukostic Leukamia.cell Physiol biochem.2018,48(2):731-740 ]. Extensive studies have demonstrated that the deficiency of this gene is a significant cause of hemolysin protein intolerance (LPI) [ Sperandeo MP, et al., lysine protein internalization: update and extended mutation analysis of the SLC7A7gene. hum. mutat.2008,29(1):14-21 ]. Furthermore, cation transporter dysfunction due to the SLC7A7 mutation is associated with a variety of clinical conditions, such as hyperammonemia, renal dysfunction, gastrointestinal symptoms, abnormal hematopoiesis, growth retardation and osteoporosis [ Ji X, et al. function of SLC7A7in T-Cell Acute lysometric leukemia, 2018,48(2):731-740 ]. High expression of SLC7A7 is highly correlated with prognosis of glioblastoma and multiple myeloma, resistance to ovarian cancer, and radiation therapy sensitivity of lung cancer [ Fan S, et al genetic variants in SLC7A7 ear associated with a saline of diabetes in a bone disease delivery. exp Biol Med (Maywood),2013,238: 1075-1081; agnelli L, et al, the redirection of translational network access computers with an indication for a clinical outome of multiple myelomas, clin Cancer Res.2011,17: 7402-; cheng L, et al, analysis of chemical stress programs in auxiliary combustors by the next-generation sequence technologies Gynecol Oncol 2010,117:159-169 ]. Recent studies have also found that SLC3a2, which is also a member of the solute carrier family, plays an important role in replication of hepatitis c virus.
However, at present, no report about the effects of the ABCC3 and SLC7A7 molecules in virus infected host cells exists, and intensive research on the two molecules can not only improve the understanding of EV71 infection and pathogenic mechanisms, but also provide a new idea and target point for preventing and treating EV71 infection.
Disclosure of Invention
The invention aims to provide a novel target for resisting enterovirus 71infection, namely a soluble carrier family 7member 7(SLC7A 7).
It is another object of the invention to provide novel uses of the solute carrier family 7member 7(SLC7a7) molecule, particularly in combating enterovirus type 71infection.
The third objective of the invention is to provide siRNA interfering with the expression of solute carrier family 7member 7(SLC7A7) molecule and application thereof.
In order to achieve the purpose, the main technical scheme of the invention is as follows:
according to the invention, a human colon cancer cell (Caco-2) is taken as a target cell, and the expression of a target cell transfer related membrane protein is reduced by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting EV71 from infecting the human colon cancer cell (Caco-2) is searched, and the purpose of blocking EV71 infection from a source (intestinal tract) is achieved. The invention selects a group of host cell transport-related membrane proteins for screening, and the molecules play an important role in the transport of transmembrane substances of host cells, the endocytosis and secretion of vesicles, and are molecules which are easy to be hijacked and utilized by viruses in the virus infection process. These molecules include: ATP-binding cassette transmembrane transport subfamily C member 3(ABCC3), ADAM metalloprotease 10(ADAM10), ADP ribosylation factor 6(ARF6), caveolin 1(CAV1), developmental and differentiation enhancing factor 2(DDEF2), tyrosine protein kinase FYN, golgi histone 1(GORASP1), huntingin interacting protein 1-related protein (HIP1R), intersection-1 (ITSN1), solute carrier family 7member 7(SLC7a7), vesicle-related membrane protein 1(VAMP1), vesicle-related membrane protein 2(VAMP2), VAMP-related protein a (vapa), and villin 2(VIL 2). The influence on EV71 infection is observed by retrieving the complete sequence and mRNA sequence from NCBI GeneBank, performing biological analysis on the genes by using the existing network resources and common software, selecting a coding region as a target sequence for siRNA design, then designing siRNA, and down-regulating the molecules.
Experiments show that the solute carrier family 7member 7(SLC7A7) plays an important role in EV71 infected Caco-2 cells, the expression of SLC7A7 is reduced, and the EV71 infection can be obviously inhibited.
Based on this, in a first aspect of the invention, a new target against enterovirus type 71infection is provided, i.e. the lysosome carrier family 7member 7(SLC7a 7).
In a second aspect of the invention, there is provided the use of member 7 of the solute carrier family 7(SLC7a7) in the manufacture of a medicament for the prophylaxis or treatment of an enterovirus type 71infection.
Further, the use is directed to the use of solute carrier family 7member 7(SLC7a7) as an intervention target for the prevention or treatment of enterovirus type 71infection.
Further, the diseases caused by the enterovirus 71infection include, but are not limited to, hand-foot-and-mouth disease, meningitis, brainstem encephalitis, poliomyelitis and the like. That is, the invention also provides the use of solute carrier family 7member 7(SLC7a7) in the preparation of a medicament for the prevention or treatment of a disease caused by an enterovirus type 71infection, including but not limited to hand-foot-and-mouth disease, meningitis, brainstem encephalitis, or poliomyelitis.
Further, the medicament is a medicament for inhibiting enterovirus 71infection by inhibiting or down-regulating the expression level of solute carrier family 7member 7(SLC7a 7).
In a third aspect of the invention, there is provided use of an agent that inhibits or down-regulates the expression level of solute carrier family 7member 7(SLC7a7) in the manufacture of a medicament for the prevention or treatment of an enterovirus type 71infection.
Further, the reagent for inhibiting or down-regulating the expression level of SLC7a7 refers to siRNA, shRNA, miRNA or antisense nucleotide which specifically interferes with expression and processing of SLC7a7gene, or a recombinant vector (such as plasmid) containing siRNA, shRNA, miRNA or antisense nucleotide.
In one embodiment of the invention, the agent that inhibits or down-regulates the expression of SLC7a7 is an interfering RNA (sirna) of member 7 of the solute carrier family 7, the interfering RNA having a sequence selected from any one of:
CUCUUAACCUUCAUUAACU(SEQ ID NO:28)、
GGCACCACCAUUAAGAAAU(SEQ ID NO:29)、
AGUUAAUGAAGGUUAAGAG(SEQ ID NO:30)。
wherein, the siRNA shown in SEQ ID NO. 29 has the best effect of reducing the expression level of SLC7A7, and the infection of the EV71 to Caco-2 cells is most obviously reduced.
In a fourth aspect of the invention, there is provided a medicament for the prophylaxis or treatment of enterovirus type 71infection, said medicament comprising an agent which inhibits or down-regulates the expression of SLC7a 7.
The invention has the advantages that:
the invention screens out a new host cell molecule SLC7A7 which can inhibit EV71 from infecting Caco-2 cells. After the SLC7A7gene is down-regulated, the normal physiological function of cells is not influenced, but the infection of the Caco-2 cells by EV71 is obviously inhibited. Therefore, the invention provides a new target and a treatment scheme for clinically preventing and treating the hand-foot-and-mouth disease, the nervous system and the cardiopulmonary system diseases caused by the EV71 infection.
Drawings
FIG. 1 is a graph showing the relative expression level and cytotoxicity of a target gene after transfection of effective siRNA, in which the major axis (left y axis) represents the relative expression level (expressed as RQ value) of the target gene detected by real-time quantitative fluorescence PCR (RT-PCR) method, and the minor axis (right y axis) represents the toxicity of each siRNA transfected into cells detected by CCK-8 kit (expressed as the cell survival rate from the normalization to the idling control group);
CTRL: caco-2 cell group without any siRNA transfection (free-run control group);
siRNA: caco-2 cell group transfected with siRNA against each target gene (experimental group);
*：p<0.05。
FIG. 2 is a graph of immunofluorescence to determine the effect of down-regulation of transport-associated membrane proteins on EV71 infection, where A is a fluorescence view of viral infectivity after down-regulation of proteins and B is a statistical graph of viral infectivity relative to an idling control group after down-regulation of molecules;
CTRL: caco-2 cell group without any siRNA transfection (free-run control group);
NT: a Caco-2 cell group (negative control group) transfected with non-targeting siRNA;
siRNA: caco-2 cell group (Experimental group) transfected with siRNA against each target Gene
Horizontal dotted line: reference line for 50% virus infection rate relative to the idling control group.
FIG. 3 shows that after transfection of siRNA targeting ABCC3 and SLC7A7 with different sequences, real-time fluorescence quantitative PCR (RT-PCR) method is used to detect mRNA level of target gene (expressed by RQ value of the relative expression of ABCC3 and SLC7A7 gene);
CTRL: caco-2 cell group without any siRNA transfection (free-run control group);
NT: a Caco-2 cell group (negative control group) transfected with non-targeting siRNA;
ABCC 3-1: a Caco-2 cell group transfected with siRNA (SEQ ID NO:1) against ABCC3 gene;
ABCC 3-2: a group of Caco-2 cells transfected with siRNA (SEQ ID NO:2) against the ABCC3 gene;
ABCC 3-3: a Caco-2 cell group transfected with siRNA (SEQ ID NO:3) against ABCC3 gene;
SLC7A 7-28: a Caco-2 cell group transfected with siRNA (SEQ ID NO:28) against the SLC7A7 gene;
SLC7A 7-29: a Caco-2 cell group transfected with siRNA (SEQ ID NO:29) against the SLC7A7 gene;
SLC7A 7-30: a Caco-2 cell group transfected with siRNA (SEQ ID NO:30) against the SLC7A7 gene;
*：p<0.05。
FIG. 4 shows the effect of down-regulation of ABCC3 and SLC7A7 on EV71 infection, wherein A and B are the viral RNA load (expressed as the relative expression RQ value of EV71 RNA) measured by RT-PCR method, and C and D are the viral protein expression measured by Western Blot method;
CTRL: caco-2 cell group without any siRNA transfection (empty cell group);
NT-CTRL: a Caco-2 cell group (negative control group) transfected with non-targeting siRNA;
ABCC 3-1: a Caco-2 cell group transfected with siRNA (SEQ ID NO:1) against ABCC3 gene;
ABCC 3-2: a group of Caco-2 cells transfected with siRNA (SEQ ID NO:2) against the ABCC3 gene;
ABCC 3-3: a Caco-2 cell group transfected with siRNA (SEQ ID NO:3) against ABCC3 gene;
SLC7A 7-28: a Caco-2 cell group transfected with siRNA (SEQ ID NO:28) against the SLC7A7 gene;
SLC7A 7-29: a Caco-2 cell group transfected with siRNA (SEQ ID NO:29) against the SLC7A7 gene;
SLC7A 7-30: a Caco-2 cell group transfected with siRNA (SEQ ID NO:30) against the SLC7A7 gene;
GAPDH, internal reference protein glyceraldehyde-3-phosphate dehydrogenase (36 kDa);
*：p<0.05。
Detailed Description
The following examples are provided to illustrate specific embodiments of the present invention, but the practice of the present invention is not limited thereto.
The reagents and starting materials used in the present invention are commercially available or can be prepared according to literature procedures. Experimental procedures without specific conditions noted in the following examples, generally following conventional conditions such as Sambrook et al molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), either according to conventional conditions or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are by weight.
Example 1:
1, designing and synthesizing specific siRNA sequence of each transport-associated membrane protein.
1.1 aiming at each target gene, NCBI GeneBank is searched to obtain the complete sequence and mRNA sequence, the AXIIR is biologically analyzed by utilizing the existing network resources and common software, and the coding region is selected as the target sequence for siRNA design. Referring to the siRNA design principle, comparing the blast function of a GeneBank database with a human genome sequence to ensure no homology; potential siRNA of pairing 8 continuous basic groups at the 5' end of the aitisense chain with other genes is excluded; any potential siRNA with a stretch of 14 consecutive bases pairing with other genes is excluded. And pre-evaluation determination is carried out by using design software, 3 optimal kinetic parameter targets are selected to enter a subsequent experimental process, and 3 interference sequences are synthesized by each gene in total, which is shown in table 1.
1.2 Synthesis and purification of Single-stranded siRNA was accomplished by Invitrogen.
TABLE 1 design of siRNA targets
2 siRNA sequence screening and interference effect identification
2.1 RNA transfection
The transfection procedure was performed according to the instruction of DharmaFECT-1 (available from Horizon, cat. No. T-2001-02)
1) Caco-2 cells (purchased from ATCC under the designation HTB-37) at 3X 104The cells were seeded in 24-well cell culture plates, cultured at 37 ℃ and transfected with siRNA at a cell density of about 70%.
2) Adding 4. mu.L DharmaFECT-1 into 46. mu.L opti-MEM, mixing, and incubating at room temperature for 5 min; another 5. mu.L of siRNA at a concentration of 5. mu.M was mixed with 46. mu.L of opti-MEM. After incubation, diluted DharmaFECT-1 transfection reagent was added to the diluted siRNA and gently pipetted and mixed. After incubation at room temperature for 15min, the cells were added to Caco-2 cells and supplemented with 400. mu.L of opti-MEM to give a final RNA concentration of 50 nM.
3) DMEM medium (purchased from Thermo Fisher scientific, Inc., Cat. 12430062) containing 10% fetal bovine serum (purchased from Thermo Fisher scientific, Inc., Cat. 10437028) was replaced at 6-8 hours.
2.2 real-time fluorescent quantitative PCR (RT-PCR) detection of mRNA levels of respective target proteins
1) Extracting total RNA of each group of cells, and the specific steps are as follows:
after 48 hours of transfection, the culture supernatant was removed, and 1ml of RNAasso Plus (purchased from TAKARA, cat # 9109) was added to the cells, and the cells were lysed on ice with thorough mixing for 5-10 minutes. The mixture was transferred to an EP tube, 1/5 volumes of chloroform were added, and shaking vigorously for 15 seconds. Centrifuge at 12,000 rpm for 15 minutes at 4 ℃. The upper aqueous phase was transferred to a new EP tube, an equal volume of isopropanol was added, mixed well and allowed to stand at room temperature for 10 minutes. Centrifuge at 12,000 rpm for 10 minutes at 4 ℃. The supernatant was discarded and 1ml of ice-cold 75% ethanol was added. Centrifuge at 12,000 rpm for 10 minutes at 4 ℃. The supernatant was discarded sufficiently, the RNA precipitate was air-dried at room temperature, and RNase Free dH was added2O) dissolving the precipitate to obtain total RNA.
2) Total cDNA was prepared using a reverse transcription kit (purchased from TAKARA, Inc., cat # RR036A) by the following specific steps:
the following reaction system was added to the PCR tube,
5×PrimeScript RT Master Mix 2μL
Total RNA 500ng
Rnase Free dH2O up to 10μL
the mixture was gently mixed and mixed, and the mixture was reacted at 37 ℃ for 15 minutes (reverse transcription reaction) and then inactivated at 85 ℃ for 5 seconds (reverse transcriptase inactivation reaction).
3) RT-PCR detection of target gene expression level
The reaction was carried out using TB Green Premix Ex Taq kit (purchased from TAKARA, Inc., cat # RR420A) in the following reaction system,
two-step amplification was performed using an Applied Biosystems 7300plus instrument:
the first step is as follows: pre-denatured at 95 ℃ for 30 seconds,
4) and calculating the relative expression quantity of each target gene by adopting a delta t method.
RQ＝2-ΔΔt＝2- [ (Ct treatment sample target Gene-Ct control sample target Gene) - (Ct treatment sample internal reference Gene-Ct control sample internal reference Gene)]
Interference efficiency is 1-RQ
3 cytotoxicity assay
The CCK-8 method is adopted to detect the influence of the transfected siRNA on cell proliferation, and the specific steps are as follows:
cells in the logarithmic growth phase were collected and seeded at a density of 3000 per well in 96-well plates. Cells were cultured to about 70% confluence, each siRNA was transfected, cultured for 48 hours, the original medium was discarded, 100. mu.L of a fresh medium containing 10. mu.L of CCK-8 reagent (purchased from Nippon college chemical research institute, cat # CK04) was added to each well, and absorbance at a wavelength of 450nm was measured in each well using a multifunctional microplate reader after 3 to 4 hours of culture. The experiment was independently repeated 3 times, the mean was calculated, and the results were normalized to the idling control group.
4 EV71 virus infection Caco-2 cell
4.1 experiment of EV71 Virus infection with Caco-2 cells
The EV71 virus infection experiment is carried out 48 hours after Caco-2 cells are transfected with siRNA. The culture supernatant was aspirated, rinsed 2 times with pre-warmed PBS, EV71 was inoculated with a virus amount of MOI 0.1, incubated at 37 ℃ for 2 hours, the virus solution was discarded, rinsed 3 times with pre-warmed PBS, and the culture was continued with addition of fresh medium.
4.2 immunofluorescence staining detection of EV71 antigen expression
The Caco-2 cells are continuously cultured for 48h after being infected with the virus, and the expression of the virus antigen is detected by adopting an immunofluorescence method, and the method comprises the following specific steps:
1) cell fixation and membrane penetration: removing culture medium from 96-well plate, adding PBS to wash cells for 2 times, adding 100 μ l of precooled methanol (with fixing and membrane permeation functions) into each well, fixing the membrane permeation at-20 deg.C for 20min, and washing cells with precooled PBS for 3 times.
2) And (3) sealing: mu.l of 3% BSA was added to each well and incubated for 1h at room temperature.
3) Primary antibody incubation: 100. mu.l of EV 71-specific murine mAb 10F0(1:1000 dilution) was added to each well, incubated overnight at 4 ℃ in a shaker, and washed 3 times with pre-cooled PBS.
4) And (3) secondary antibody incubation: 100. mu.l of AF 488 fluorescence-labeled anti-mouse IgG (diluted 1: 1000) was added to each well, incubated at room temperature for 1h in the dark, and washed 3 times with pre-cooled PBS in the dark.
5) Marking cell nucleus: cell nucleus fluorescent dye DAPI (1:10000, PBS dilution) was added to each well, incubated at room temperature in the dark for 15min, and washed 3 times with pre-cooled PBS in the dark.
6) The green AF 488-positive cell rate was detected and calculated under a fluorescence microscope.
4.3 Western blot.
(1) And respectively extracting the total protein of each group of Caco-2 cells by using protein lysate.
(2) After protein quantification, 20ug of protein was added to 10% SDA-PAGE gels, and the corresponding bands were removed and transferred to PVDF membrane using an electrotransfer.
(3) Non-specific sites of the protein were blocked with 5% skim milk, incubated with diluted EV 71-specific murine mAb 10F0(1:1000 dilution) overnight at 4 ℃ and rinsed three times with TBST buffer.
(4) The cells were then incubated with HRP-labeled goat anti-rabbit IgG (1:1000 dilution) for 2 hours at room temperature, followed by three washes with TBST buffer.
(5) And finally, developing by using a developing solution and photographing for analysis.
4.4RT-PCR detection of the amount of EV71 Virus in cells
And (3) continuously culturing the Caco-2 cells for 48h after the Caco-2 cells are infected with the virus, extracting total RNA of the cells of the control group and the interference group by using TRIzol, carrying out reverse transcription to obtain cDNA, and detecting the amount of the EV71 virus by RT-PCR. The specific steps are as shown in 2.2.
The experimental results are as follows:
1 design, Synthesis and screening of effective siRNA
Aiming at each target gene sequence, a plurality of RNA interference target sequences are designed, pre-evaluation determination is carried out by utilizing design software, 3 optimal kinetic parameter targets are selected to enter a subsequent experimental process, and each gene is synthesized into 3 interference sequences in total, as shown in table 1.
The in vitro transfection method is adopted, the interfering RNA of each gene is transfected into Caco-2 cells, the relative expression quantity of each target gene (shown in table 2) is detected by an RT-PCR method after 48 hours, and finally, the siRNA sequence with the best interference effect (the sequence is added in table 2) is screened out for subsequent experiments.
TABLE 2 RT-PCR method for detecting the relative expression of target genes after siRNA transfection
Note: CTRL: caco-2 cell group without any siRNA transfection (free-run control group);
NT: a Caco-2 cell group (negative control group) transfected with non-targeting siRNA;
siRNA: caco-2 cell group (experimental group) transfected with siRNA against each gene of interest.
2 interference efficiency and cytotoxicity assays after siRNA interference
The selected effective siRNA aiming at each host molecule is used for transfecting Caco-2 cells, the relative expression quantity of each target gene is detected by an RT-PCR method 48h after transfection, and the CCK8 is used for detecting the influence on Caco-2 cytotoxicity after transfection.
As shown in FIG. 1, the group transfected with effective siRNA was able to significantly suppress the expression level of the corresponding gene (P < 0.05) after transfection of each siRNA, compared with the group CTRL. The interference efficiency of the transfection ABCC3 siRNA (SEQ ID NO:1) and SLC7A7 siRNA (SEQ ID NO:29) is as high as 87.82 and 88.44%, respectively.
The cytotoxicity experiment shows that after each siRNA transfection, obvious cytotoxicity (P is more than 0.05) is not generated, the normal physiological function of cells is not influenced, and the siRNA can be used for subsequent experiments.
3 Effect of siRNA interference on EV71 Virus infection
After the effective siRNA of each host molecule is transfected to down-regulate the expression of related molecules of the host cell, EV71 virus with the same dosage is infected, after 48h of infection, the influence of the down-regulated host molecules on EV71 infection is detected by adopting an immunofluorescence method, and the fact that the ABCC3 siRNA (SEQ ID NO:1) and the SLC7A7 siRNA (SEQ ID NO:29) are transfected to down-regulate the ABCC3 gene and the SLC7A7gene respectively and then the infection of the EV71 to Caco-2 cells is obviously reduced (figure 2A) compared with a control group is found. By calculating the virus amount, the inhibition rates of ABCC3 and SLC7A7 genes on the virus after being down-regulated reach 87.05% and 81.66%, respectively, and the down-regulation of the rest molecules does not obviously inhibit the infection of EV71 on Caco-2 cells (P > 0.05) (figure 2B).
To further clarify the important roles of ABCC3 and SLC7a7in EV71 infection, the effect on viral infectivity was observed after transfection of three sirnas against ABCC3 and SLC7a7 molecules, respectively. The siRNA interference efficiency is detected by an RT-PCR method. The EV71 virus load is detected by an RT-PCR method and an immunoblotting method respectively. The results showed that different siRNAs interfered with different ABCC3 and SLC7A7 molecules with different efficiencies (FIGS. 3A, 3B), with ABCC3 siRNA (SEQ ID NO:1) and SLC7A7 siRNA (SEQ ID NO:29) with the highest interference efficiency, consistent with the previous results. The influence of interference on EV71 infectivity is detected, the inhibition rate of siRNA of three ABCC3 molecules and three SLC7A7 molecules on virus infection can reach more than 50%, and the virus amount in Caco-2 cells is also remarkably reduced along with the increase of interference efficiency on ABCC3 molecules and SLC7A7 molecules (figures 4A-4D), which is consistent with the detection result of an immunofluorescence method. These results indicate that the ABCC3 and SLC7A7 molecules play an important role in EV71 infection of Caco-2 cells.
Therefore, ABCC3 and SLC7A7 can be used as new host targets for inhibiting EV71 from infecting Caco-2 cells.
The above experimental results prove that: the invention screens two new host cell molecules ABCC3 and SLC7A7 which can inhibit EV71 from infecting Caco-2 cells. After the ABCC3 and SLC7A7 genes are down-regulated, the normal physiological functions of cells are not influenced, but the infection of the Caco-2 cells by the EV71 is obviously inhibited. Therefore, the invention provides a new target and a treatment scheme for clinically preventing and treating EV71 infection.
While the preferred embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that the invention is not limited thereto, and that various changes and modifications may be made without departing from the spirit of the invention, and the scope of the appended claims is to be accorded the full range of equivalents.
Sequence listing
<110> second military medical university of China people liberation army
Application of <120> solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71 type infection
<130> /
<160> 42
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 1
cgcugaucuu acaacacua 19
<210> 2
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 2
gcugaucuua caacacuau 19
<210> 3
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 3
uaguguugua agaucagcg 19
<210> 4
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 4
gcuaauggcu ggauuuauu 19
<210> 5
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 5
cccaaagucu cucacauua 19
<210> 6
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 6
gcaagggaag gaauaugua 19
<210> 7
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 7
ccucuaacua caaaucuua 19
<210> 8
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 8
ggaaggugcu auccaaaau 19
<210> 9
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 9
ggauacaacu aaaguacga 19
<210> 10
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 10
cuaaacaccu caacgauga 19
<210> 11
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 11
gcaguuguac caugcauua 19
<210> 12
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 12
gcaaauacgu agacucgga 19
<210> 13
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 13
gaaauccgca uugcagguu 19
<210> 14
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 14
cgagauagca aacgaguca 19
<210> 15
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 15
gguccucugu ccaaugcua 19
<210> 16
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 16
gcucugaaau uaccaaauc 19
<210> 17
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 17
cgcaugaauu auauccaua 19
<210> 18
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 18
cugugaagca uucgagaca 19
<210> 19
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 19
cuggaggugu ucaauauga 19
<210> 20
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 20
gaggacuucu uuacgcuca 19
<210> 21
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 21
gaucucuacc acagaauaa 19
<210> 22
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 22
cagcucaacu cgugaacua 19
<210> 23
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 23
cuguggagau guuugauua 19
<210> 24
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 24
ccucuucgau cagacguuu 19
<210> 25
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 25
ggacauaguu guacugaaa 19
<210> 26
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 26
gauaucagau gucgauuga 19
<210> 27
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 27
ggccauaacu guagaggaa 19
<210> 28
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 28
cucuuaaccu ucauuaacu 19
<210> 29
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 29
ggcaccacca uuaagaaau 19
<210> 30
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 30
aguuaaugaa gguuaagag 19
<210> 31
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 31
cuccuaacau gaccaguaa 19
<210> 32
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 32
caucacaauu ugagagcag 19
<210> 33
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 33
ccaucaucgu gguaguuau 19
<210> 34
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 34
uaguuuacuu cagcucuua 19
<210> 35
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 35
gcgcaaauac ugguggaaa 19
<210> 36
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 36
ccuccaaacc ucaccagua 19
<210> 37
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 37
ccacagaccu caaauucaa 19
<210> 38
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 38
ggcaaaaccu gaugaauua 19
<210> 39
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 39
ccugagagau gaagguuua 19
<210> 40
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 40
gcucaaagau aaugcuaug 19
<210> 41
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 41
ggcaacagcu ggaaacaga 19
<210> 42
<211> 19
<212> RNA
<213> Artificial sequence (Artificial)
<400> 42
caagaaggca ccugacuuu 19
Claims (3)
1. Use of an agent that inhibits or down-regulates the expression level of a member 7 of solute carrier family 7in the manufacture of a medicament for the prevention or treatment of enterovirus type 71 infection; the reagent for inhibiting or reducing the expression quantity of the solute carrier family 7member 7 refers to siRNA, shRNA, miRNA or antisense nucleotide which specifically interferes with the expression and processing of the solute carrier family 7member 7gene, or a recombinant vector containing siRNA, shRNA, miRNA or antisense nucleotide.
2. The use according to claim 1, wherein the use of an agent that inhibits or down-regulates the expression level of solute carrier family 7member 7in the preparation of a medicament for preventing or treating hand-foot-and-mouth disease, meningitis, brainstem encephalitis, or polio caused by enterovirus type 71infection.
3. The use according to claim 1, wherein the agent that inhibits or down-regulates the expression of solute carrier family 7member 7 is an interfering RNA of solute carrier family 7member 7, the nucleotide sequence of said interfering RNA being represented by any one of SEQ ID NO. 28, SEQ ID NO. 29 and SEQ ID NO. 30.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910500724.5A CN112057621B (en) | 2019-06-11 | 2019-06-11 | Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910500724.5A CN112057621B (en) | 2019-06-11 | 2019-06-11 | Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112057621A CN112057621A (en) | 2020-12-11 |
| CN112057621B true CN112057621B (en) | 2021-07-02 |
Family
ID=73658275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910500724.5A Active CN112057621B (en) | 2019-06-11 | 2019-06-11 | Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112057621B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118059246B (en) * | 2024-04-18 | 2024-07-05 | 呈诺再生医学科技(北京)有限公司 | New use of cyclic RNA CIRCSLC A4 expression promoter in colorectal cancer diagnosis and treatment |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103611167A (en) * | 2013-11-25 | 2014-03-05 | 中国人民解放军第二军医大学 | Application of miR-106a in inhibiting expression and glucose uptake of glioma cell SLC2A3 |
| CN105267984A (en) * | 2015-01-21 | 2016-01-27 | 中国人民解放军第二军医大学 | Application of ADP ribosylation factor 6 in prevention and treatment of enterovirus 71 infection |
| CN105267948A (en) * | 2015-05-29 | 2016-01-27 | 中国人民解放军第二军医大学 | Applications of hepatocyte growth factor-regulated tyropsine kinasesubstrate in preparation of medicines preventing enterovirus 71-type infection |
| CN105288655A (en) * | 2015-05-29 | 2016-02-03 | 中国人民解放军第二军医大学 | Application of vacuolar protein sorting 4A to preparing medicines for preventing or treating enterovirus type 71 infection |
| CN105535975A (en) * | 2015-12-21 | 2016-05-04 | 中国人民解放军第二军医大学 | Applications of vesicle-associated membrane protein 1 in prevention and treatment of enterovirus 71 infection |
-
2019
- 2019-06-11 CN CN201910500724.5A patent/CN112057621B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103611167A (en) * | 2013-11-25 | 2014-03-05 | 中国人民解放军第二军医大学 | Application of miR-106a in inhibiting expression and glucose uptake of glioma cell SLC2A3 |
| CN105267984A (en) * | 2015-01-21 | 2016-01-27 | 中国人民解放军第二军医大学 | Application of ADP ribosylation factor 6 in prevention and treatment of enterovirus 71 infection |
| CN105267948A (en) * | 2015-05-29 | 2016-01-27 | 中国人民解放军第二军医大学 | Applications of hepatocyte growth factor-regulated tyropsine kinasesubstrate in preparation of medicines preventing enterovirus 71-type infection |
| CN105288655A (en) * | 2015-05-29 | 2016-02-03 | 中国人民解放军第二军医大学 | Application of vacuolar protein sorting 4A to preparing medicines for preventing or treating enterovirus type 71 infection |
| CN105535975A (en) * | 2015-12-21 | 2016-05-04 | 中国人民解放军第二军医大学 | Applications of vesicle-associated membrane protein 1 in prevention and treatment of enterovirus 71 infection |
Non-Patent Citations (7)
Also Published As
| Publication number | Publication date |
|---|---|
| CN112057621A (en) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation | |
| Qian et al. | SNORD126 promotes hepatitis C virus infection by upregulating claudin-1 via activation of PI3K-AKT signaling pathway | |
| Zhang et al. | An RNA Interference/Adeno‐Associated Virus Vector–Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus | |
| CN112057621B (en) | Application of solute carrier family 7member 7in preparation of medicine for preventing and treating enterovirus 71infection | |
| Son et al. | JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis | |
| Jiang et al. | Hsp90 regulates GCRV-II proliferation by interacting with VP35 as its receptor and chaperone | |
| Zhang et al. | BmNPV circular RNA-encoded peptide VSP39 promotes viral replication | |
| Nam et al. | Radicicol inhibits chikungunya virus replication by targeting nonstructural protein 2 | |
| Wang et al. | Genome-scale CRISPR screen identifies TRIM2 and SLC35A1 associated with porcine epidemic diarrhoea virus infection | |
| Nagashima et al. | Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform | |
| CN105267948B (en) | Application of the tyrosine kinase substrate that hepatocyte growth factor is adjusted in preparation prevention and treatment enterovirns type 71 infection medicine | |
| CN112057622B (en) | Application of ATP (adenosine triphosphate) binding cassette transmembrane transport subfamily C member 3 in preparation of medicine for preventing and treating enterovirus 71infection | |
| Yang et al. | Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes | |
| Son et al. | Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model | |
| CN105535975B (en) | Application of the vesicle-associated membrane albumen 1 in prevention enterovirns type 71 infection | |
| Wang et al. | Inhibition of lysosome-tethered Ragulator-Rag-3D complex restricts the replication of Enterovirus 71 and Coxsackie A16 | |
| Lu et al. | siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells | |
| CN105288655B (en) | Application of the vacuole sorting protein 4A in preparation prevention and treatment enterovirns type 71 infection medicine | |
| Zhu et al. | Up-regulated 60S ribosomal protein L18 in PEDV N protein-induced S-phase arrested host cells promotes viral replication | |
| CN105497918B (en) | Application of dynamin 1in preventing and treating enterovirus 71infection | |
| CN105267984B (en) | Application of the ADP ribosylation factor 6 in prevention and treatment enterovirns type 71 infection | |
| CN110585431B (en) | Application of interleukin 4receptor in preparing medicament for preventing and treating enterovirus 71 type infection | |
| CN110585432B (en) | Application of fibroblast growth factor receptor 1in preparation of medicine for preventing and treating enterovirus 71infection | |
| CN105288654B (en) | Application of the protein tyrosine kinase FYN oncogene in prevention and treatment enterovirns type 71 infection | |
| CN105435245B (en) | Application of the calcium integrin Binding Protein 1 in prevention and treatment enterovirns type 71 infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |